Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 46
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02109627 | Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | ||
| NCT02090127 | Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient | ||
| NCT01478594 | A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy | ||
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | ||
| NCT03136627 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | ||
| NCT01673386 | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC | ||
| NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | ||
| NCT00717340 | A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer | ||
| NCT01210846 | A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors | ||
| NCT01306630 | A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors | ||
| NCT04100330 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT01039948 | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | ||
| NCT01316848 | A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects | ||
| NCT01363804 | A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects | ||
| NCT01297244 | A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | ||
| NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label | ||
| NCT06053658 | Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | ||
| NCT05865535 | A Dose Escalation Study of AV-380 in Metastatic Cancer Patients with Cachexia | ||
| NCT02627963 | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) | ||
| NCT00551850 | A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients | ||
| NCT00969410 | A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases | ||
| NCT01076010 | An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). | ||
| NCT01058655 | RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer | ||
| NCT01603979 | A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors | ||
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma | ||
| NCT01782313 | A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas | ||
| NCT02277184 | Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma | ||
| NCT04987203 | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | ||
| NCT01835223 | Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery | ||
| NCT03316599 | Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer | ||
| NCT01972516 | Tivozanib As Maintenance Therapy In GYN | ||
| NCT00725634 | A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma | ||
| NCT01807156 | Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer | ||
| NCT01769885 | Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer | ||
| NCT00502307 | A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma | ||
| NCT00826878 | An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC) | ||
| NCT01363778 | A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects | ||
| NCT02277197 | Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | ||
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma | ||
| NCT01631097 | A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function | ||
| NCT01369433 | A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols | ||
| NCT00660153 | Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers | ||
| NCT00563147 | A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma | ||
| NCT06064877 | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | ||
| NCT04815551 | A Phase 1 Study of AV-380 in Healthy Subjects | ||
| NCT00381654 | Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies |
